Modulation of C5a-C5aR interactions against murine mammary cancer cell line

Complement C5a is a potent inflammatory chemoattractant and might be a beneficial therapeutic target for the induction of an effective anti-tumour response. C5a agonist and antagonist modulation have been demonstrated to either promote or inhibit tumour development in EMT6 murine mammary cancer cell...

Full description

Bibliographic Details
Main Authors: Kamarudin, N. H., Bachek, N. F., Mohd Noor, Mohd Hezmee
Format: Article
Published: Springer 2021
Online Access:http://psasir.upm.edu.my/id/eprint/94241/
_version_ 1848861944761548800
author Kamarudin, N. H.
Bachek, N. F.
Mohd Noor, Mohd Hezmee
author_facet Kamarudin, N. H.
Bachek, N. F.
Mohd Noor, Mohd Hezmee
author_sort Kamarudin, N. H.
building UPM Institutional Repository
collection Online Access
description Complement C5a is a potent inflammatory chemoattractant and might be a beneficial therapeutic target for the induction of an effective anti-tumour response. C5a agonist and antagonist modulation have been demonstrated to either promote or inhibit tumour development in EMT6 murine mammary cancer cells in both in vitro and in vivo studies. For the in vitro studies Alamar Blue cell viability assay was used for cell viability determination, and an immunofluorescence assay was used to determine the location of C5aR expression on the EMT6 cell line. For the in-vivo experiment, female Balb/c mice were subcutaneously injected with EMT6 tumour cells and subsequently treated with both C5aR agonist and antagonist peptides. At the end of the in vivo study period of 14 days, liver and tumour samples were obtained for an ELISA assay to quantify the levels of TNF-α, caspase, C5a and VEGF-A signals following treatment with both C5aR agonist and antagonist. The in vitro experiment revealed that an expression of C5aR was found on the cell membrane of the EMT6 cells, and treatment with EP54, which is a C5aR agonist, showed low cell viability 48 h posttreatment. For the in vivo experiment, the ELISA assay outcome showed that EP54 significantly promoted higher numbers of circulating signalling proteins except for VEGF-A, suggesting that the C5aR agonist modulation might inhibit tumour growth and also trigger the induction of apoptosis.
first_indexed 2025-11-15T13:09:11Z
format Article
id upm-94241
institution Universiti Putra Malaysia
institution_category Local University
last_indexed 2025-11-15T13:09:11Z
publishDate 2021
publisher Springer
recordtype eprints
repository_type Digital Repository
spelling upm-942412023-05-09T01:54:46Z http://psasir.upm.edu.my/id/eprint/94241/ Modulation of C5a-C5aR interactions against murine mammary cancer cell line Kamarudin, N. H. Bachek, N. F. Mohd Noor, Mohd Hezmee Complement C5a is a potent inflammatory chemoattractant and might be a beneficial therapeutic target for the induction of an effective anti-tumour response. C5a agonist and antagonist modulation have been demonstrated to either promote or inhibit tumour development in EMT6 murine mammary cancer cells in both in vitro and in vivo studies. For the in vitro studies Alamar Blue cell viability assay was used for cell viability determination, and an immunofluorescence assay was used to determine the location of C5aR expression on the EMT6 cell line. For the in-vivo experiment, female Balb/c mice were subcutaneously injected with EMT6 tumour cells and subsequently treated with both C5aR agonist and antagonist peptides. At the end of the in vivo study period of 14 days, liver and tumour samples were obtained for an ELISA assay to quantify the levels of TNF-α, caspase, C5a and VEGF-A signals following treatment with both C5aR agonist and antagonist. The in vitro experiment revealed that an expression of C5aR was found on the cell membrane of the EMT6 cells, and treatment with EP54, which is a C5aR agonist, showed low cell viability 48 h posttreatment. For the in vivo experiment, the ELISA assay outcome showed that EP54 significantly promoted higher numbers of circulating signalling proteins except for VEGF-A, suggesting that the C5aR agonist modulation might inhibit tumour growth and also trigger the induction of apoptosis. Springer 2021-05-27 Article PeerReviewed Kamarudin, N. H. and Bachek, N. F. and Mohd Noor, Mohd Hezmee (2021) Modulation of C5a-C5aR interactions against murine mammary cancer cell line. Comparative Clinical Pathology, 30. 549 - 557. ISSN 1618-5641; ESSN: 1618-565X https://link.springer.com/article/10.1007/s00580-021-03249-6 10.1007/s00580-021-03249-6
spellingShingle Kamarudin, N. H.
Bachek, N. F.
Mohd Noor, Mohd Hezmee
Modulation of C5a-C5aR interactions against murine mammary cancer cell line
title Modulation of C5a-C5aR interactions against murine mammary cancer cell line
title_full Modulation of C5a-C5aR interactions against murine mammary cancer cell line
title_fullStr Modulation of C5a-C5aR interactions against murine mammary cancer cell line
title_full_unstemmed Modulation of C5a-C5aR interactions against murine mammary cancer cell line
title_short Modulation of C5a-C5aR interactions against murine mammary cancer cell line
title_sort modulation of c5a-c5ar interactions against murine mammary cancer cell line
url http://psasir.upm.edu.my/id/eprint/94241/
http://psasir.upm.edu.my/id/eprint/94241/
http://psasir.upm.edu.my/id/eprint/94241/